Alliances
Illumina is teaming up with Loxo Oncology to develop and commercialize a multi-gene panel for broad cancer profiling. It will seek approval for a version of Illumina’s TruSight Tumor 170 as a companion diagnostic for Loxo Oncology’s larotrectinib and LOXO-292.
Investors in Ionis Pharmaceuticals are happy this morning after the company announced it struck another licensing deal with AstraZeneca that has the potential to yield up to $330 million.
Danish pharma giant Novo Nordisk tied up a sickle cell and beta-thalassemia program in a $400 million deal with Ohio-based EpiDestiny.
The FDA issued two Complete Response Letters (CRLs) to South Korean manufacturer Celltrion. Teva Pharmaceutical Industries signed a deal in 2016 with Celltrion to commercialize the two biosimilars.
Eidos Therapeutics closed on a $64 million Series B financing round. The funds will be used to advance the company’s product candidate, AG10, into Phase II clinical trials and Phase III trials.
U.S. sales of AbbVie’s blockbuster Humira is safe from a biosimilar challenge from Samsung Bioepis, a joint project between Samsung and Biogen, until 2023.
Boehringer Ingelheim and OSE Immunotherapeutics signed a collaboration and license deal to jointly develop OSE-172 for myeloid cancers.
After winning Amgen’s coveted 2017 Golden Ticket in December 2017 startup company QurAlis officially launched with financial backing from Amgen Ventures with a mission to develop a cure for Amyotrophic Lateral Sclerosis (ALS).
Shares of Conatus Pharmaceuticals dropped 34.3 percent postmarket yesterday after the San Diego-based company announced mixed top-line results for its proof-of-concept trial in liver transplant patients with fibrosis or cirrhosis.
Allergan and its developmental partner Gedeon Richter Ltd. are eying an add-on approval from the U.S. Food and Drug Administration for a depression treatment based on new Phase III data released Tuesday.
PRESS RELEASES